Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells $97,951.17 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini sold 2,399 shares of the firm’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $40.83, for a total value of $97,951.17. Following the transaction, the general counsel now directly owns 47,088 shares of the company’s stock, valued at approximately $1,922,603.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Jeff Cislini also recently made the following trade(s):

• On Wednesday, June 26th, Jeff Cislini sold 2,000 shares of Revolution Medicines stock. The stock was sold at an average price of $38.47, for a total transaction of $76,940.00.

Revolution Medicines Price Performance

Shares of Revolution Medicines stock traded down $1.46 during trading on Wednesday, hitting $42.46. 1,538,144 shares of the company’s stock traded hands, compared to its average volume of 1,350,429. Revolution Medicines, Inc. has a 1 year low of $15.44 and a 1 year high of $44.80. The business has a 50-day simple moving average of $38.76 and a 200-day simple moving average of $33.61. The stock has a market capitalization of $7.01 billion, a P/E ratio of -11.71 and a beta of 1.44.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.05. Revolution Medicines’s revenue was down 100.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.72) earnings per share. On average, equities analysts predict that Revolution Medicines, Inc. will post -3.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC increased its position in shares of Revolution Medicines by 140.9% during the 1st quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock valued at $49,000 after purchasing an additional 885 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in Revolution Medicines by 10.6% during the fourth quarter. Teacher Retirement System of Texas now owns 23,375 shares of the company’s stock valued at $670,000 after buying an additional 2,238 shares during the last quarter. ProShare Advisors LLC raised its position in Revolution Medicines by 6.8% in the first quarter. ProShare Advisors LLC now owns 36,605 shares of the company’s stock worth $1,180,000 after acquiring an additional 2,331 shares during the period. Manchester Capital Management LLC purchased a new position in shares of Revolution Medicines during the 4th quarter worth $80,000. Finally, Amalgamated Bank boosted its stake in shares of Revolution Medicines by 18.7% during the 4th quarter. Amalgamated Bank now owns 18,495 shares of the company’s stock worth $530,000 after acquiring an additional 2,908 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Analyst Ratings Changes

RVMD has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $44.00 price objective on shares of Revolution Medicines in a report on Monday, May 13th. Jefferies Financial Group began coverage on Revolution Medicines in a research note on Monday. They issued a “buy” rating and a $63.00 price target on the stock. Wedbush lifted their price objective on Revolution Medicines from $42.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, May 9th. Oppenheimer boosted their target price on Revolution Medicines from $43.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, April 12th. Finally, Raymond James upgraded Revolution Medicines from an “outperform” rating to a “strong-buy” rating and raised their price target for the company from $36.00 to $48.00 in a report on Wednesday, April 10th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $45.00.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.